首页|期刊导航|中华医学杂志（英文版）|XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer

XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer

ZHU Xiao-li CHENG Lu LU Zu-hong SUN Xin-chen CHEN Bao-an SUN Ning CHENG Hong-yan LI Fan ZHANG Hong-ming FENG Ji-feng QIN Shu-kui

中华医学杂志（英文版）2010，Vol.123Issue(23)：3427-3432,6.

中华医学杂志（英文版）2010，Vol.123Issue(23)：3427-3432,6.DOI:10.3760/cma.j.issn.0366-6999.2010.23.010

XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer

ZHU Xiao-li ¹CHENG Lu ²LU Zu-hong ³SUN Xin-chen ⁴CHEN Bao-an ⁵SUN Ning ⁶CHENG Hong-yan ⁷LI Fan ⁷ZHANG Hong-ming ⁷FENG Ji-feng ⁷QIN Shu-kui⁷

作者信息

1. Department of Respiratory Diseases,Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, China
2. Department of Oncology ,Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, China
3. Department of Hematology,Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, China
4. Department of Oncology, Jiangsu Cancer Hospital, Nanjing,Jiangsu 210009, China
5. Department of Oncology, 81th Hospital of People's Liberation Army, Nanjing, Jiangsu 210034, China
6. State Key Laboratory of Bioelectronics, Southeast University,Nanjing, Jiangsu 210096, China
折叠

摘要

Abstract

Background Platinum-based chemotherapeutics are the most common regimens for advanced non-small-cell lung cancer (NSCLC) patients, and genetic factors are thought to represent important determinants of drug efficacy. We prospectively assessed the status of the XPC Ala499Val and Lys939GIn gene polymorphisms and investigated whether these SNPs can predict the response to cisplatin/carboplatin-based regimens in advanced NSCLC patients in a Chinese population.Methods The treatment outcomes of 96 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. The polymorphic status of xeroderma pigmentosum group C (XPC) gene was genotyped by the 3-D polyacrylamide gel-based DNA microarray method.Results The distributions of XPC Lys939GIn genotypes differed significantly between the response group (complete +partial responses) and the non-response group (stable + progressive disease; P=0.022). The heterozygous A/C genotype carriers had a poorer response rate than the wild A/A genotype carriers in stage Ⅲ (OR, 0.074; 95% CI,0.008-0.704; P=0.023). The XPC Ala499Val polymorphisms were not associated with response to platinum-based chemotherapy.Conclusion Polymorphisms of the XPC gene, Lys939GIn, may be a predictive marker of treatment response for advanced NSCLC patients in stage Ⅲ.

关键词

single nucleotide polymorphism/gene-chip/microarray/xeroderma pigmentosum group C/non-small-cell lung cancer/chemotherapy

Key words

single nucleotide polymorphism/gene-chip/microarray/xeroderma pigmentosum group C/non-small-cell lung cancer/chemotherapy

分类

医药卫生

引用本文复制引用

ZHU Xiao-li,CHENG Lu ,LU Zu-hong,SUN Xin-chen,CHEN Bao-an,SUN Ning,CHENG Hong-yan,LI Fan,ZHANG Hong-ming,FENG Ji-feng,QIN Shu-kui..XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer[J].中华医学杂志（英文版）,2010,123(23):3427-3432,6.

基金项目

This work was supported by the grants from the Prophase Force-Study Program of the Jiangsu Province Natural Science Foundation (No. BK2005203), the Medical Science Technology Research "Eleventh Five-Year" Program of the People's Liberation Army (No. 06MA 111), and the Focal Project of Nanjing Medical Technology Development (No. ZKX05030). （No. BK2005203）

中华医学杂志（英文版）

OACSCDCSTPCDMEDLINESCI

ISSN：0366-6999

访问量0

下载量0

段落导航